Peter Kaiser

Featured in: Favicon

nature.com Favicon

mdpi.com

sagepub.com Favicon

aao.org

dovepress.com Favicon

healio.com Favicon

hcplive.com Favicon

pinkbike.com Favicon

mondaq.com Favicon

ophthalmologytimes.com (+1) + 8 more

Articles

VIDEO: OTX-TKI moves toward phase 3 trial for treatment of diabetic retinopathy

Jan 24, 2025 | healio.com | Peter Kaiser |Anthony DeFino |Eamon Dreisbach

January 24, 2025 1 min read VIDEO: OTX-TKI moves toward phase 3 trial for treatment of diabetic retinopathy Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Retina/Vitreous in Ophthalmology. Subscribe Added to email alerts You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published.
VIDEO: Ocular Therapeutix shifts to retina-focused treatments

Nov 11, 2024 | healio.com | Peter Kaiser |Anthony DeFino |Eamon Dreisbach

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, ofOcular Therapeutix, discusses the company’s shift to a retina-focused program.
Upfront: A Fond Farewell

Oct 31, 2024 | retinalphysician.com | Peter Kaiser

In January 2012, I channeled my inner Steve Jobs to cajole electronic medical record companies to “think different” about the future of EMR. It was my first Upfront as editor-in-chief of Retinal Physician. One hundred and seven Upfronts later, it is with a heavy heart that I announce that this is my last. In January, the new editor in chief, Diana Do, MD, of Byers Eye Institute at Stanford, will take over this enviable position and enlighten us in her unique way as she takes the helm.
Upfront: Time for Fewer, But Stronger, Retina Societies

Oct 1, 2024 | retinalphysician.com | Peter Kaiser

This year, both the American Society of Retina Specialists (ASRS) and the Retina Society held their annual meetings across the pond. This is not surprising, because all the societies move their annual meeting to an international location every few years. However, on the rare occasions that the international meetings overlap, as they did this year, most US retina specialists will have to choose which one to attend.
Upfront: How Far We've Come

Sep 1, 2024 | retinalphysician.com | Peter Kaiser

I was at my nephew’s home the other day and watched the kids play College Football 25 by EA Sports. The game was in glorious 4k and the players truly looked alive. The game play was incredible, using plays from the actual college playbooks. It boggles the mind to think how sophisticated the programming behind this game is. Videogames are a $100 billion industry, so I am sure EA Sports spent millions developing the title.
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI) | Eye

Aug 26, 2024 | nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more

The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).
Implementing Higher Molar Dose in Your Clinical Practice

Jul 24, 2024 | modernretina.com | John W. Kitchens |Peter Kaiser

July 24, 2024By John Kitchens, MD, and Peter Kaiser, MD, discuss drug duration, accelerating dosing intervals, and other pearls for aflibercept dosing in wet AMD. In this podcast, John Kitchens, MD, is joined by Peter Kaiser, MD. They discuss higher molar dose and share pearls and their clinical best practices. What are the challenges when treating patients with higher molar doses? How can clinicians help patients transition to a higher dose? Listen and find out today.
Higher Molar Dose and Its Translation into Clinical Practice

Jul 22, 2024 | europe.ophthalmologytimes.com | John W. Kitchens |Peter Kaiser

July 22, 2024By John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice. They also discussed the challenges they face in treating patients with higher molar doses, including insurance limitations, safety concerns and convincing insurance carriers to switch to a new dose. They shared clinical pearls for helping patients transition to a higher dose. Increasing aflibercept dose for longer drug duration in eyes.
Upfront: Same Retinal Physician, New Platform

Jul 1, 2024 | retinalphysician.com | Peter Kaiser

As children, many of us made money as paperboys delivering newspapers on our bicycles to local homes and businesses. It was a set route, which was especially difficult on Sundays when the papers were filled with coupons and extra flyers. Reading the Sunday comics was a weekly highlight. There were minimal other sources of information before the internet.
Upfront: New Efforts to Halt Diabetic Eye Disease

Jun 1, 2024 | retinalphysician.com | Peter Kaiser

In 1994, the Centers for Disease Control and Prevention (CDC) declared diabetes mellitus an epidemic. By 2021, 1 in 10 adults worldwide had diabetes. One in 5 Americans over age 65 had diabetes. One in 3 American adults had impaired glucose tolerance and were prediabetic. Look to your left and right; one of you will have diabetes shortly.